Closure of Trading Window under SEBI (Prohibition of Insier Trading) Regulations, 2015 for the period ending on December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Oxygenta Pharmaceutical has informed the BSE that its trading window will remain closed from January 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending December 31, 2025. The restriction applies to all designated persons, their immediate relatives, and connected persons covered under the company's insider trading code. The Board Meeting to consider and approve these Q3 (October–December 2025) financial results will be announced separately. The closure is a standard compliance measure under SEBI's insider trading norms ahead of results declaration.
This is a routine regulatory filing. The trading window closure prevents insiders from trading shares until results are published, which means no insider action signals are present. Investors should wait for the upcoming Q3 FY26 results announcement for any fundamental triggers on the stock.